Role of a probiotic strain in the modulation of gut microbiota and cytokines in inflammatory bowel disease

From BugSigDB
Needs review
Citation
PMID PubMed identifier for scientific articles.
DOI Digital object identifier for electronic documents.
URI
Authors
Bamola VD, Dubey D, Samanta P, Kedia S, Ahuja V, Madempudi RS, Neelamraju J, Chaudhry R
Journal
Anaerobe
Year
2022
Keywords:
Bacillus clausii UBBC-07, Cytokines, Gut microbiome, IBD, Probiotic
OBJECTIVE: To assess the effect of a probiotic strain Bacillus clausii UBBC-07 on gut microbiota and cytokines in IBD patients. METHOD: Patients were randomly allocated to either placebo or probiotic Bacillus clausii UBBC-07 for four weeks along with the standard medical treatment (SMT). Enrolled patients were evaluated before and after intervention for presence of the given probiotic, change in gut microbiota, change in serum cytokines, serotonin and dopamine, symptoms of disease, physical, behavioral and psychological parameters. RESULTS: Probiotic strain Bacillus clausii UBBC-07 showed good survival in IBD patients in the treatment group (p < 0.01) without any reported adverse event. Metagenomic analysis showed that the given probiotic strain was able to modulate the gut microbiota in treated group. Phylum Firmicutes was increased and phylum Bacteroidetes was decreased in the probiotic treated group. A significant increase was observed in the abundance of anaerobic bacterial genera Lactobacillus, Bifidobacterium and Faecalibacterium in the probiotic treated group (p < 0.01) as compared to placebo group. Significant increase was observed in IL-10 (p < 0.05) and variable decrease in the secretion of IL-1β, TNF- α, IL-6, IL -17 and IL -23 in probiotic treated group. In the treatment group a significant decrease in the symptoms of IBD and improvement in the psychological parameter to various degrees was noted. CONCLUSION: These results indicated that probiotic strain B clausii UBBC-07 affected the gut microbiota and cytokine secretion and shown efficacy in IBD patients.

Experiment 1


Needs review

Curated date: 2023/03/11

Curator: Brian

Revision editor(s): Brian, Atrayees, Aiyshaaaa, Peace Sandy, Folakunmi

Subjects

Location of subjects
India
Host species Species from which microbiome was sampled. Contact us to have more species added.
Homo sapiens
Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces
Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
inflammatory bowel disease autoimmune bowel disorder,Bowel Diseases, Inflammatory,IBD,INFLAMM BOWEL DIS,inflammatory bowel disease,Inflammatory Bowel Diseases
Group 0 name Corresponds to the control (unexposed) group for case-control studies
Placebo group before intervention/treatment
Group 1 name Corresponds to the case (exposed) group for case-control studies
Bacillus clausii UBBC-07 group after intervention/treatment
Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
Patients who were treated with Bacillus clausii UBBC-07 and evaluated after treatment/intervention for the effect of the probiotic on gut microbiota. Patients were of either sex, clinically diagnosed with Ulcerative Colitis or Crohn's Disease, and between 18 and 60 years.
Group 0 sample size Number of subjects in the control (unexposed) group
54
Group 1 sample size Number of subjects in the case (exposed) group
54

Lab analysis

Sequencing type
16S
16S variable region One or more hypervariable region(s) of the bacterial 16S gene
V3-V4
Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
Illumina

Statistical Analysis

Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
relative abundances
Statistical test
Kruskall-Wallis
Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
0.01
MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
No


Signature 1

Needs review

Curated date: 2023/10/17

Curator: Folakunmi

Revision editor(s): Folakunmi

Source: Text (Results)

Description: Differentially abundant taxa in Bacillus clausii UBBC-07 group post intervention/treatment

Abundance in Group 1: increased abundance in Bacillus clausii UBBC-07 group after intervention/treatment

NCBI Quality ControlLinks
Bacillota
Lactobacillus
Bifidobacterium
Faecalibacterium

Revision editor(s): Folakunmi

Signature 2

Needs review

Curated date: 2023/10/18

Curator: Folakunmi

Revision editor(s): Folakunmi

Source: Text (Results)

Description: Differentially abundant taxa in Bacillus clausii UBBC-07 group post intervention/treatment

Abundance in Group 1: decreased abundance in Bacillus clausii UBBC-07 group after intervention/treatment

NCBI Quality ControlLinks
Bacteroidia

Revision editor(s): Folakunmi